{
    "clinical_study": {
        "@rank": "152893", 
        "acronym": "Talent", 
        "arm_group": [
            {
                "arm_group_label": "Conrol", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo\uff0c3 capsules/time\uff0c3times/day for 1 year"
            }, 
            {
                "arm_group_label": "Tongxinluo", 
                "arm_group_type": "Experimental", 
                "description": "Tongxinluo 3 capsules/time 3times/day for 1 year"
            }
        ], 
        "brief_summary": {
            "textblock": "Tongxinluo is a kind of Chinese patent drug,which could promote blood circulation.Recent\n      reports suggested that tongxinluo's effectiveness in reducing the thrombin activity.In this\n      prospective randomized study,all patients in control group will receive blank placebo ,all\n      patients in test group will receive tongxinluo.All patients will be followed up for one\n      year."
        }, 
        "brief_title": "Tongxinluo Improve High on Clopidogrel Platelet Reactivityn Patients With Coronary Heart Disease", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary endpoint is Platelet aggregation rate( by VerifyNow) at 30 days.The secondary\n      endpoints include inflammation marker (hsCRP\u3001CD62P-CD41),BT\u3001FIB and APTT at 30 days,and\n      MI\u3001Ischemic Stroke and all-cause mortality \u3001bleeding events at 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - (1)ACS (including unstable angina pectoris, non-ST-segment elevation myocardial\n        infarction and ST-elevation myocardial infarction) \uff082\uff09Accept at least one coronary stent.\n        \uff083\uff09The age between18 and 75 . \uff084\uff09High on-treatment platelet reactivity defined as an\n        ADP-induced platelet aggregation (by VerifyNow\uff0cPRU\u2265236\uff09at 24 hr after clopidogrel loading\n        (300 ~ 600mg)or 24 hours after PCI.\n\n        \uff085\uff09Informed Consent\n\n        Exclusion Criteria:\n\n          -  \uff081\uff09Tongxinluo contraindication . \uff082\uff09Receiving GP IIb / IIIa receptor antagonist\n             treatment \uff083\uff09Who complicate the known bleeding tendency and blood system diseases.\n             \uff084\uff09NYHA grade III ~ IV \uff085\uff09Aspirin or clopidogrel allergies \uff086\uff09Severe liver or kidney\n             dysfunction \uff087\uff09Pregnancy \uff088\uff09Cann't accept 30 days supervision and blood proofer.\n             \uff089\uff09Other serious illness, life expectancy less than 6 months. \uff0810) Planned surgery\n             recently \uff0811) PCI again within 30 days. (12) Mental diseases interfering\n             understanding the informed consent form \uff0813\uff09Accept other drugs or participate in\n             other clinical research at the same time ."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721590", 
            "org_study_id": "SYNH-20120929"
        }, 
        "intervention": {
            "arm_group_label": "Tongxinluo", 
            "description": "Tongxinluo", 
            "intervention_name": "Tongxinluo", 
            "intervention_type": "Drug", 
            "other_name": "Tongxinluo capsule"
        }, 
        "intervention_browse": {
            "mesh_term": "Clopidogrel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "high on-treatment platelet reactivity", 
            "Coronary Heart Disease", 
            "Tongxinluo"
        ], 
        "lastchanged_date": "November 1, 2012", 
        "location": [
            {
                "contact": {
                    "last_name": "Lu Li, MD", 
                    "phone": "13309882525"
                }, 
                "facility": {
                    "address": {
                        "city": "ShengYang", 
                        "country": "China", 
                        "state": "Liaoning", 
                        "zip": "110032"
                    }, 
                    "name": "ShenZhou Hopital Of ShenYang Medical College"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "13998847715@qq.com", 
                    "last_name": "Yaling Han, Dr", 
                    "phone": "+86-24-23922184"
                }, 
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning"
                    }, 
                    "name": "Northern Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Yaling Han, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Yi Li, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Lei Zhang, MBBS", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Meiling Ge, MBBS", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hongyun Zang, MD", 
                    "phone": "15309885517"
                }, 
                "facility": {
                    "address": {
                        "city": "ShenYang", 
                        "country": "China", 
                        "state": "Liaoning", 
                        "zip": "110042"
                    }, 
                    "name": "The 463th Hospital Of PLA"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of Tongxinluo to Improve High on Clopidogrel Platelet Reactivity in Patients With Coronary Heart Disease", 
        "overall_contact": {
            "email": "13998847715@qq.com", 
            "last_name": "Yaling Han, MD", 
            "phone": "+86-24-23922184"
        }, 
        "overall_official": {
            "affiliation": "Shenyang Northern Hospital", 
            "last_name": "Yaling Han, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Platelet aggregation rate( by VerifyNow)", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721590"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shenyang Northern Hospital", 
            "investigator_full_name": "Yaling Han", 
            "investigator_title": "vice president", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Inflammation Marker (hsCRP\u3001CD62P-CD41)", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "BT\u3001FIB and APTT", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Including MI\u3001Ischemic Stroke and all-cause mortality", 
                "measure": "Major Ischemia event", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "bleeding event", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Adverse drug reaction and withdrawal rate", 
                "safety_issue": "Yes", 
                "time_frame": "1 month \uff0c1 year"
            }, 
            {
                "measure": "Angina recurrence", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Traditional Chinese medicine angina symptoms scores", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Intra-stent thrombosis", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Shenyang Northern Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yaling Han", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}